An Analysis of Class I Recalls: 1982

Abstract

Class I recalls possess the greatest degree of health hazard and are frequently conducted to the consumer or user level. This study analyzes all Class I recalls appearing in the Food and Drug Administration (FDA) Enforcement Reports from 1982–1996. Major causes of Class I recalls over the past 14 years include: drug quality and good manufacturing practices (GMP) violations, mislabeling, and adverse reactions. Class I recalls over this time period are analyzed by reason, brand versus generic company, dosage form (eg, injection, tablet), notification method, and further FDA enforcement action (eg, seizure, injunction, criminal prosecution). Trends are identified. Finally, the effectiveness of Class I recalls to the pharmacy level is assessed.

Keywords

Class I recalls;Mislabeling;Brand versus generic;Dosage form;Recall notification

Get full access to this article

View all access options for this article.

References

43 Federal Register 26202 (1978).

Fine

Recalls—Definition and exposition. Food Drug Cosmetic Law J. 1972;27:662–671.

Harper

Mandatory food and drug recalls. An analysis of a developing FDA enforcement tool. Food Drug Cosmetic Law J. 1981;35:669–687.

Rumore

The drug product recall system and the pharmacist: Are consumers protected?

N.Y. State J. Health Syst Pharm. 1996;15(10):137–159.

FDA Enforcement Manual. Tab 600. Recalls and administrative injunction. Thompson Publications Group, Inc.; 1992:44.

FDA Regulatory Procedures Manual. Part 5, Ch. 5.00–20. Recall and emergency procedures.

Clevenger

Recalls. Food, Drug, Cosmetic Law J. 1972;27:332–343.

Parker

Valentino

Handling a pharmaceutical recall: why it pays to do it right. Drug Inf J. 1994;28:899–813.

Labeling/packaging error recalls down 43% in 1996. The Pink Sheet. T&G 6–7, January 20, 1997.

10.

FDA seeks labeling regulation changes, disclosure of clinical trials in preliminary legislative agenda. FDC Reports—The Pink Sheet. 59(11):3–4, March 17, 1997.

11.

Gumbhir

Jamison

Assessing the effectiveness of drug recalls in pharmacies. Drug & Cosmetic Ind. 1975;117:40–43, 113.

12.

U.S.P. Quality Review. The U.S.P. Convention. 8/96.

An Analysis of Class I Recalls: 1982–1996 *

Abstract

Keywords

Get full access to this article

References